←
Raja Khauli MD FACS687 posts
Raja Khauli MD FACS avatar✓

Raja Khauli MD FACS ✓

@FacsRaja

Professor of Urology & Surgery Urologic Oncology and Robotics American University of Beirut-MED Adjunct Professor of Urology University of Massachusetts

◷ Joined March 2016▧ 23 Photos and videos
Dra. María Natalia Gandur Quiroga avatar
⟳ Raja Khauli MD FACS retweeted
Dra. María Natalia Gandur Quiroga@nataliagandur·Nov 14

⭐🔵 #UromigosLive 2026 | Nashville 🇺🇸 🚨 PROTEUS: FROM PATHOLOGIC RESPONSE TO CLINICAL BENEFIT! 📊 Phase III | N=2,109 Apalutamide + ADT vs placebo + ADT, perioperatively. ✅ pCR/MRD: 8.9% vs 1.0% ✅ 5-year MFS: 78.2% vs 73.5% ✅ MFS HR 0.80 (95% CI 0.67–0.96) 🔬 PROTEUS substudy | N=408 APA + ADT + RP vs RP alone: ✅ EFS HR 0.38 (95% CI 0.26–0.55) ✅ 3-year EFS: 63% vs 41.4% 💡 MY POV: Intensification is promising, but patient selection, toxicity and long-term benefit remain essential! 🎙️ @OncoAlert @brian_rini @AttardLab @NehaVapiwala @dr_coops @tompowles1 @Uromigos @neerajaiims @TDorffOnc @silkegillessen @AOmlin #ProstateCancer #UroVoices

Post attachmentPost attachmentPost attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ Raja Khauli MD FACS retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·Nov 13

🧬 Can urine EV glycan signatures help us distinguish aggressive prostate cancer from indolent disease BEFORE committing patients to biopsy? lnkd.in/exDkkJ4d Extracellular vesicle glycan profiling for pre-biopsy detection of prostate cancer Could urine extracellular vesicle (EV) glycan profiling improve #ProstateCancer detection beyond PSA? ➡️ In this study of 135 men, Glycoflow analysis of post-DRE urine EVs improved discrimination of clinically significant prostate cancer (AUC 0.80 vs 0.71–0.72) and very significant disease (0.81–0.82 vs 0.72–0.73) when combined with clinical parameters. ✅ EV glycan profiling provided complementary diagnostic information, potentially improving biopsy decisions and reducing overdiagnosis, pending larger validation. @sim1garz8 @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Post attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ Raja Khauli MD FACS retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·Nov 5

🧬 Are we underestimating rare prostate cancer histologies simply because we rarely look for them? nature.com/articles/s41585-0… Rare prostate cancer histologies: detection, characteristics and treatment Rare #ProstateCancer histologies comprise less than 5% of cases but represent a clinically important and under-recognized group. ➡️These subtypes often show aggressive behaviour, atypical metastatic patterns and poorer outcomes, while remaining underrepresented in guidelines and trials. ➡️Accurate diagnosis increasingly depends on multiparametric MRI, immunohistochemistry and genomic profiling. ➡️Molecular alterations such as DNA🧬 repair defects, TP53/RB1 loss and mismatch repair deficiency may offer therapeutic opportunities, highlighting the need for subtype-specific evidence and prospective studies. @bavilima , @UrogerliMD, @katcollmd, @neerajaiims, @PGrivasMDPhD, @Albert0Briganti, @AndreaNecchi, @LiangChengMD, @SpiessPhilippe @Oncoalert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Post attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ Raja Khauli MD FACS retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·Nov 2

Should high-risk prostate cancer go straight to surgery? PROTEUS finally offers a head-to-head answer: preoperative apalutamide + ADT vs prostatectomy alone 👇 cslide.ctimeetingtech.com/es… LBA53 - Perioperative apalutamide (APA) plus androgen-deprivation therapy (ADT) with radical prostatectomy plus pelvic lymph node dissection (RP + PLND) vs RP + PLND alone in patients (pts) with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): PROTEUS substudy PROTEUS’s prespecified open-label substudy randomized 408 patients with high-risk localized or locally advanced #ProstateCancer 1:3 to perioperative apalutamide plus ADT or immediate radical prostatectomy plus lymphadenectomy alone. ➡️Apalutamide plus ADT significantly improved event-free survival (median not reached vs 19.1 months; HR 0.38) and MFS (HR 0.49), and reduced the need for subsequent therapy at 3 years (35% vs 68%). Grade 3/4 adverse events were higher with apalutamide (30.7% vs 21.7%). @Albert0Briganti, @EfstathiouEleni, @ProfHadaschik, @adamkibel_uro, @delataillealex, @marty_gleave @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Post attachment
OncoAlert avatar
⟳ Raja Khauli MD FACS retweeted
OncoAlert@OncoAlert·Nov 4

Live from Lugano Series in Prostate Cancer OncoAlert🚨 × APCCC 🇨🇭 In this Episode Prof Ian Davis @Prof_IanD ( @EHCSMonash 🇦🇺 Melbourne @ANZUPtrials ) and Dr Alicia Morgans @CaPsurvivorship ( @DanaFarber 🇺🇸Boston) talk about IRONMAN, the global #ProstateCancer registry. Hearing every patient’s voice in prostate cancer 🌍 💡 Takeaways: 🔹 IRONMAN is close to its goal of about 5,000 patients at 110–115 sites on every continent except Antarctica 🔹 It collects treatment data, blood samples, concomitant medications and PROMs to study real-world sequencing and outcomes 🔹 Researchers anywhere can apply to use the data or set up sub-studies 🎓 Series Faculty @APCCC_Lugano · @BertrandTOMBAL · @ChrisSweens1 · @jmmrad · @drjefstathiou · @CaPsurvivorship · @LoebStacy · @charlesryanmd · @AarmstrongDuke · @Ecastromarcos · @LVM_Walz · @piet_ost · @Nicola_Fossati · @AnthonyMJoshua · @Prof_Nick_James · @VedangMurthy · @AttardLab · @Silke_Gillessen · @AOmlin · @ProfKHerrmann 📣 Also tagging @gu_onc · @tompowles1 · @brian_rini · @declangmurphy · @cdanicas · @neerajaiims @mzugman @AmandaNizamMD · @scocmem · @nataliagandur ·

3:49
Adam B. Weiner, MD avatar
⟳ Raja Khauli MD FACS retweeted
Adam B. Weiner, MD@Adam_Weiner535·Oct 31

🚨 PROTEUS substudy (@EUplatinum): perioperative apalutamide + ADT improves event-free survival vs radical prostatectomy alone in high-risk/locally advanced #prostatecancer, 🧵 1/3 🚨 👥 408 pts, high-risk localized or locally advanced PCa, fit for surgery 📊 Open-label phase 3 substudy, randomized 1:3 💊 Perioperative (neoadj + adj) apalutamide + ADT (n=102) vs RP alone (n=306) ⏱️ Median f/u 37.4 mo ⭐️Event = BCR or imaging-based recurrence ✅ 3-yr EFS 63% vs 41%, HR 0.38 (0.26-0.55), p<0.001 ✅ MFS by conventional or PSMA PET 87% vs 78%, HR 0.49 (0.26-0.90) ✅ But MFS by conventional imaging alone: similar, 94% vs 92% (p=0.5) ⚠️Caution in interpretation - See thread 👇 🔗 doi.org/10.1016/j.eururo.202… @PCFnews @PCF_Science @urotoday @UrologyTimes @TylerSbrt @renalandurology @Uroweb @JackAndrewsMD

Post attachmentPost attachmentPost attachmentPost attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ Raja Khauli MD FACS retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·Oct 28

‼️ On 134 key questions in prostate cancer care, experts reached consensus on just 44. What does that tell us about the evidence guiding treatment — and where do we need better answers? 📄 Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference 🔗 sciencedirect.com/science/ar… At #APCCC26, 144 international experts 🌐 tackled challenging clinical questions where high-level evidence remains limited. Using a modified Delphi process, 133 panellists voted on 134 questions covering high-risk localised, locally advanced and biochemically recurrent prostate cancer, including PSA persistence, PSA recurrence and treatment-related side effects. ✅ Consensus (≥75% agreement) was reached on just 44 questions (32.8%), with strong consensus (≥90%) on only seven. 👉 Where experts disagree, the need for better evidence is clear. Areas without consensus highlight important priorities for future clinical trials. @Silke_Gillessen, @AOmlin, @Prof_Nick_James, @LVM_Walz, @AOmlin, @AttardLab, @bjartell, @LoebStacy, @Tilki_De, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @VedangMurthy, @neerajaiims, @Achard_Verane, @PBlanchardMD, @lisahorvath73, @BarbaraJereczek, @fontev1, @ChrisSweens1, @AarmstrongDuke, @CharlesRyanMD, @ProfKHerrmann, @KarimFizazi, @NealShore, @himishabeltran, @HeatherChengMD, @DrRanaMcKay, @AliciaMorgansMD, @declangmurphy, @DrSpratticus, @EvanYuMD, @NehaVapiwalaMD, @drjefstathiou, @BertrandTOMBAL @OncoAlert 🚨 #ProstateCancer #APCCC26

Post attachment